K. Kalkner

发表

Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer

S. Acosta, M. Stridsberg, B. Gustavsson, 2006, Prostate Cancer and Prostatic Diseases.

Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.

S. Nilsson, J. Laissue, J. Reubi, 1995, Cancer research.

Elevated serum levels of soluble ICAM-1 are elevated in non-Hodgkin´s lymphomas and correlate with tumor burden, disease activity and other diagnostic markers

H. Hagberg, I. Christiansen, H. Bennmarker, 1996 .

Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma.

M. Bergström, G. Antoni, B. Långström, 1997, Nuclear medicine and biology.